Kevin Boyd

3.3k total citations
83 papers, 2.0k citations indexed

About

Kevin Boyd is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Kevin Boyd has authored 83 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Hematology, 45 papers in Oncology and 38 papers in Molecular Biology. Recurrent topics in Kevin Boyd's work include Multiple Myeloma Research and Treatments (61 papers), Protein Degradation and Inhibitors (28 papers) and Cancer Treatment and Pharmacology (19 papers). Kevin Boyd is often cited by papers focused on Multiple Myeloma Research and Treatments (61 papers), Protein Degradation and Inhibitors (28 papers) and Cancer Treatment and Pharmacology (19 papers). Kevin Boyd collaborates with scholars based in United Kingdom, United States and Canada. Kevin Boyd's co-authors include Faith E. Davies, Gareth J. Morgan, Brian A. Walker, Laura Chiecchio, Walter M. Gregory, Fiona M. Ross, Christopher P. Wardell, Gian Paolo Dagrada, Zoë J. Konn and Sarah Bird and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Kevin Boyd

76 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kevin Boyd United Kingdom 22 1.4k 1.3k 773 214 159 83 2.0k
C‐H Pui United States 34 1.8k 1.4× 1.1k 0.9× 1.1k 1.5× 337 1.6× 318 2.0× 47 4.2k
Siddhartha Ganguly United States 21 617 0.5× 618 0.5× 784 1.0× 161 0.8× 218 1.4× 138 1.6k
Yaël C. Cohen Israel 19 669 0.5× 389 0.3× 537 0.7× 131 0.6× 162 1.0× 141 1.4k
Peter Duggan Canada 18 841 0.6× 452 0.4× 455 0.6× 287 1.3× 181 1.1× 106 1.4k
Rik Schots Belgium 24 779 0.6× 541 0.4× 403 0.5× 92 0.4× 228 1.4× 63 1.5k
W. Lange Germany 24 599 0.4× 514 0.4× 812 1.1× 274 1.3× 383 2.4× 59 1.9k
Juan Bergua Spain 21 1.3k 1.0× 979 0.8× 739 1.0× 328 1.5× 237 1.5× 59 2.3k
Malin Hultcrantz United States 22 1.5k 1.1× 893 0.7× 516 0.7× 121 0.6× 1.1k 7.0× 113 2.2k
Arend von Stackelberg Germany 32 1.9k 1.4× 583 0.5× 917 1.2× 381 1.8× 277 1.7× 92 3.3k
Margareth C. Ozelo Brazil 26 1.6k 1.1× 1.0k 0.8× 535 0.7× 51 0.2× 380 2.4× 122 2.8k

Countries citing papers authored by Kevin Boyd

Since Specialization
Citations

This map shows the geographic impact of Kevin Boyd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Boyd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Boyd more than expected).

Fields of papers citing papers by Kevin Boyd

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Boyd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Boyd. The network helps show where Kevin Boyd may publish in the future.

Co-authorship network of co-authors of Kevin Boyd

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Boyd. A scholar is included among the top collaborators of Kevin Boyd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Boyd. Kevin Boyd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Messiou, Christina, Núria Porta, Dow‐Mu Koh, et al.. (2025). Whole body MRI by MY-RADS for imaging response assessment in multiple myeloma. Blood Cancer Journal. 15(1). 122–122.
2.
Cairns, David A., Charlotte Pawlyn, Eugene B. Ferris, et al.. (2025). Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling. Blood. 146(22). 2670–2680.
3.
Jenner, Matthew, et al.. (2025). Management of relapsed multiple myeloma: A British Society of Haematology and UK Myeloma Society guideline. British Journal of Haematology. 207(6). 2322–2354.
4.
5.
Jones, John R, David A. Cairns, Charlotte Pawlyn, et al.. (2023). Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial. EClinicalMedicine. 62. 102099–102099. 9 indexed citations
6.
Cairns, David A., Amy Holroyd, Charlotte Pawlyn, et al.. (2022). Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial. Blood. 141(14). 1666–1674. 21 indexed citations
7.
8.
Bird, Sarah, Charlotte Pawlyn, Priya Sriskandarajah, et al.. (2020). A real‐world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple‐myeloma patients. British Journal of Haematology. 191(5). 927–930. 7 indexed citations
9.
Latifoltojar, Arash, Kevin Boyd, Angela M. Riddell, Martin Kaiser, & Christina Messiou. (2020). Characterising spatial heterogeneity of multiple myeloma in high resolution by whole body magnetic resonance imaging: Towards macro-phenotype driven patient management. Magnetic Resonance Imaging. 75. 60–64. 15 indexed citations
10.
Chu, Karen, Steven Habbous, Qin Kuang, et al.. (2015). Socioeconomic status, human papillomavirus, and overall survival in head and neck squamous cell carcinomas in Toronto, Canada. Cancer Epidemiology. 40. 102–112. 24 indexed citations
11.
12.
Morgan, Gareth J., Graham Jackson, Faith E. Davies, et al.. (2012). Efficacy and side-effect profile of long-term bisphosphonate therapy in patients (pts) with multiple myeloma (MM): MRC myeloma IX study results.. Journal of Clinical Oncology. 30(15_suppl). 8015–8015. 1 indexed citations
13.
Boyd, Kevin, Fiona M. Ross, Laura Chiecchio, et al.. (2011). Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma. Cancer Epidemiology Biomarkers & Prevention. 20(8). 1703–1707. 33 indexed citations
14.
Boyd, Kevin, Fiona M. Ross, Brian A. Walker, et al.. (2011). Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival. Clinical Cancer Research. 17(24). 7776–7784. 131 indexed citations
15.
Boyd, Kevin, Fiona M. Ross, William Tapper, et al.. (2011). The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide‐based therapy. Genes Chromosomes and Cancer. 50(10). 765–774. 50 indexed citations
16.
Boyd, Kevin, F. M. Ross, Laura Chiecchio, et al.. (2011). A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 26(2). 349–355. 224 indexed citations
17.
Dickens, Nicholas J., Brian A. Walker, Paola Leone, et al.. (2010). Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome. Clinical Cancer Research. 16(6). 1856–1864. 85 indexed citations
18.
Schey, Stephen, Gareth J. Morgan, Karthik Ramasamy, et al.. (2010). The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. British Journal of Haematology. 150(3). 326–333. 47 indexed citations
19.
Choi, Yun‐Hee, Michelle Cotterchio, Gail McKeown‐Eyssen, et al.. (2009). Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario. Hereditary Cancer in Clinical Practice. 7(1). 14–14. 44 indexed citations
20.
Morris, T. C. M., Paul Kettle, Mary Drake, et al.. (2008). Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma. British Journal of Haematology. 143(3). 349–354. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C‐H Pui Breakdown of academic impact, for papers by Siddhartha Ganguly Breakdown of academic impact, for papers by Yaël C. Cohen Breakdown of academic impact, for papers by Peter Duggan Breakdown of academic impact, for papers by Rik Schots Breakdown of academic impact, for papers by W. Lange Breakdown of academic impact, for papers by Juan Bergua Breakdown of academic impact, for papers by Malin Hultcrantz Breakdown of academic impact, for papers by Arend von Stackelberg Breakdown of academic impact, for papers by Margareth C. Ozelo
Rankless by CCL
2026